Kinomica
Kinomica’s mission is to provide competitive intelligence to enhance tailored treatment decisions involving anticancer drug therapies.
| GBP | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 165 % | (59 %) | - | 317 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (179 %) | (195 %) | (851 %) | (780 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (196 %) | (205 %) | (823 %) | (836 %) | (211 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 147 % | - | - | - | - |
Source: Company filings or news article
Related Content
Kinomica operates in the precision medicine market, focusing on the development of a phosphoproteomic diagnostic platform. This platform aids clinicians in selecting the most effective therapy for individual patients by analyzing protein phosphorylation, which is a process that regulates protein function. The company primarily serves healthcare providers, including hospitals and specialized clinics, who are looking to improve patient outcomes through personalized treatment plans. Kinomica's business model revolves around offering diagnostic services and selling proprietary diagnostic kits. Revenue is generated through service fees and the sale of these kits. The company's innovative approach leverages advanced mass spectrometry and bioinformatics to provide actionable insights into disease mechanisms and treatment efficacy, ensuring that patients receive the right therapy at the right time.
Keywords: phosphoproteomics, precision medicine, diagnostics, protein phosphorylation, mass spectrometry, bioinformatics, personalized treatment, healthcare, patient outcomes, diagnostic kits.